Literature DB >> 32193224

Tuning the Antigen Density Requirement for CAR T-cell Activity.

Robbie G Majzner1,2, Skyler P Rietberg2, Elena Sotillo2, Rui Dong3, Vipul T Vachharajani4, Louai Labanieh5, June H Myklebust6,7, Meena Kadapakkam1, Evan W Weber2, Aidan M Tousley1, Rebecca M Richards1, Sabine Heitzeneder2, Sang M Nguyen1, Volker Wiebking1, Johanna Theruvath2, Rachel C Lynn2, Peng Xu2, Alexander R Dunn8,9, Ronald D Vale3,10, Crystal L Mackall11,2,12.   

Abstract

Insufficient reactivity against cells with low antigen density has emerged as an important cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that modulate the threshold for antigen recognition. We demonstrate that CD19 CAR activity is dependent upon antigen density and that the CAR construct in axicabtagene ciloleucel (CD19-CD28ζ) outperforms that in tisagenlecleucel (CD19-4-1BBζ) against antigen-low tumors. Enhancing signal strength by including additional immunoreceptor tyrosine-based activation motifs (ITAM) in the CAR enables recognition of low-antigen-density cells, whereas ITAM deletions blunt signal and increase the antigen density threshold. Furthermore, replacement of the CD8 hinge-transmembrane (H/T) region of a 4-1BBζ CAR with a CD28-H/T lowers the threshold for CAR reactivity despite identical signaling molecules. CARs incorporating a CD28-H/T demonstrate a more stable and efficient immunologic synapse. Precise design of CARs can tune the threshold for antigen recognition and endow 4-1BBζ-CARs with enhanced capacity to recognize antigen-low targets while retaining a superior capacity for persistence. SIGNIFICANCE: Optimal CAR T-cell activity is dependent on antigen density, which is variable in many cancers, including lymphoma and solid tumors. CD28ζ-CARs outperform 4-1BBζ-CARs when antigen density is low. However, 4-1BBζ-CARs can be reengineered to enhance activity against low-antigen-density tumors while maintaining their unique capacity for persistence.This article is highlighted in the In This Issue feature, p. 627. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32193224      PMCID: PMC7939454          DOI: 10.1158/2159-8290.CD-19-0945

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  74 in total

1.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Authors:  Claudia M Kowolik; Max S Topp; Sergio Gonzalez; Timothy Pfeiffer; Simon Olivares; Nancy Gonzalez; David D Smith; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

2.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

Authors:  Zeguo Zhao; Maud Condomines; Sjoukje J C van der Stegen; Fabiana Perna; Christopher C Kloss; Gertrude Gunset; Jason Plotkin; Michel Sadelain
Journal:  Cancer Cell       Date:  2015-10-12       Impact factor: 31.743

3.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Authors:  Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Juliane Gust; W Conrad Liles; Mark M Wurfel; José A López; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

4.  Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.

Authors:  Ayal Hendel; Rasmus O Bak; Joseph T Clark; Andrew B Kennedy; Daniel E Ryan; Subhadeep Roy; Israel Steinfeld; Benjamin D Lunstad; Robert J Kaiser; Alec B Wilkens; Rosa Bacchetta; Anya Tsalenko; Douglas Dellinger; Laurakay Bruhn; Matthew H Porteus
Journal:  Nat Biotechnol       Date:  2015-06-29       Impact factor: 54.908

5.  Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.

Authors:  Hongwei Du; Koichi Hirabayashi; Sarah Ahn; Nancy Porterfield Kren; Stephanie Ann Montgomery; Xinhui Wang; Karthik Tiruthani; Bhalchandra Mirlekar; Daniel Michaud; Kevin Greene; Silvia Gabriela Herrera; Yang Xu; Chuang Sun; Yuhui Chen; Xingcong Ma; Cristina Rosa Ferrone; Yuliya Pylayeva-Gupta; Jen Jen Yeh; Rihe Liu; Barbara Savoldo; Soldano Ferrone; Gianpietro Dotti
Journal:  Cancer Cell       Date:  2019-02-11       Impact factor: 31.743

6.  CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.

Authors:  Mohamad Hamieh; Anton Dobrin; Annalisa Cabriolu; Sjoukje J C van der Stegen; Theodoros Giavridis; Jorge Mansilla-Soto; Justin Eyquem; Zeguo Zhao; Benjamin M Whitlock; Matthew M Miele; Zhuoning Li; Kristen M Cunanan; Morgan Huse; Ronald C Hendrickson; Xiuyan Wang; Isabelle Rivière; Michel Sadelain
Journal:  Nature       Date:  2019-03-27       Impact factor: 49.962

7.  Advanced methods of microscope control using μManager software.

Authors:  Arthur D Edelstein; Mark A Tsuchida; Nenad Amodaj; Henry Pinkard; Ronald D Vale; Nico Stuurman
Journal:  J Biol Methods       Date:  2014

8.  CRISPR/Cas9 genome editing in human hematopoietic stem cells.

Authors:  Rasmus O Bak; Daniel P Dever; Matthew H Porteus
Journal:  Nat Protoc       Date:  2018-01-25       Impact factor: 13.491

9.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

10.  Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia.

Authors:  Elena J Orlando; Xia Han; Catherine Tribouley; Patricia A Wood; Rebecca J Leary; Markus Riester; John E Levine; Muna Qayed; Stephan A Grupp; Michael Boyer; Barbara De Moerloose; Eneida R Nemecek; Henrique Bittencourt; Hidefumi Hiramatsu; Jochen Buechner; Stella M Davies; Michael R Verneris; Kevin Nguyen; Jennifer L Brogdon; Hans Bitter; Michael Morrissey; Piotr Pierog; Serafino Pantano; Jeffrey A Engelman; Wendy Winckler
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

View more
  87 in total

Review 1.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

2.  CAR T cells better than BiTEs.

Authors:  John C Molina; Nirali N Shah
Journal:  Blood Adv       Date:  2021-01-26

Review 3.  [CAR T-cell therapy for malignant B-cell lymphoma : A new treatment paradigm].

Authors:  H Balke-Want; P Borchmann
Journal:  Internist (Berl)       Date:  2021-06-21       Impact factor: 0.743

4.  Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.

Authors:  Kevin R Parker; Denis Migliorini; Eric Perkey; Kathryn E Yost; Aparna Bhaduri; Puneet Bagga; Mohammad Haris; Neil E Wilson; Fang Liu; Khatuna Gabunia; John Scholler; Thomas J Montine; Vijay G Bhoj; Ravinder Reddy; Suyash Mohan; Ivan Maillard; Arnold R Kriegstein; Carl H June; Howard Y Chang; Avery D Posey; Ansuman T Satpathy
Journal:  Cell       Date:  2020-09-21       Impact factor: 41.582

Review 5.  A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

Authors:  Kathryn M Cappell; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2021-07-06       Impact factor: 66.675

6.  A rational mouse model to detect on-target, off-tumor CAR T cell toxicity.

Authors:  Mauro Castellarin; Caroline Sands; Tong Da; John Scholler; Kathleen Graham; Elizabeth Buza; Joseph A Fraietta; Yangbing Zhao; Carl H June
Journal:  JCI Insight       Date:  2020-07-23

7.  Progress and potential: The Cancer Moonshot.

Authors:  Norman E Sharpless; Dinah S Singer
Journal:  Cancer Cell       Date:  2021-05-06       Impact factor: 31.743

8.  CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.

Authors:  John H Baird; Matthew J Frank; Juliana Craig; Shabnum Patel; Jay Y Spiegel; Bita Sahaf; Jean S Oak; Sheren F Younes; Michael G Ozawa; Eric Yang; Yasodha Natkunam; John Tamaresis; Zachary Ehlinger; Warren D Reynolds; Sally Arai; Laura Johnston; Robert Lowsky; Everett Meyer; Robert S Negrin; Andrew R Rezvani; Parveen Shiraz; Surbhi Sidana; Wen-Kai Weng; Kara L Davis; Sneha Ramakrishna; Liora Schultz; Chelsea Mullins; Allison Jacob; Ilan Kirsch; Steven A Feldman; Crystal L Mackall; David B Miklos; Lori Muffly
Journal:  Blood       Date:  2021-04-29       Impact factor: 22.113

9.  Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.

Authors:  Max Jan; Irene Scarfò; Rebecca C Larson; Amanda Walker; Andrea Schmidts; Andrew A Guirguis; Jessica A Gasser; Mikołaj Słabicki; Amanda A Bouffard; Ana P Castano; Michael C Kann; Maria L Cabral; Alexander Tepper; Daniel E Grinshpun; Adam S Sperling; Taeyoon Kyung; Quinlan L Sievers; Michael E Birnbaum; Marcela V Maus; Benjamin L Ebert
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

Review 10.  Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.

Authors:  Emiliano Roselli; Rawan Faramand; Marco L Davila
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.